Chengdu, China, May 18, 2022
Anticancer Bioscience and DelSiTech Announce a Collaboration Agreement for the Development of Long-acting and Controlled Release Therapies in Oncology
Chengdu, China, May 18, 2022 – Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, based in China, and DelSiTech Ltd, the leading silica drug delivery technology company, based in Finland, today announced a notable collaboration pertaining to the development of silica-based long-acting controlled release treatments in oncology.
The collaboration joins ACB’s innovative cancer therapeutics and DelSiTech’s proprietary drug delivery technology with the aim to achieve controlled and tissue-specific release, resulting in safer treatment with improved efficiency and reduced adverse effects.
Dr. Dun Yang, Founder, President, and CEO of Anticancer Bioscience commented: “We are excited to be working with DelSiTech. The delivery of our innovative cancer therapeutics using DelSiTech’s proprietary drug delivery technology will enable us to explore novel mechanisms of action and new indications for our therapeutics. We recognize the need to partner with companies like DelSiTech who specialize in drug delivery, to maximize patient outcomes.”
Dr. Lasse Leino, CEO of DelSiTech commented: “We are excited and proud to be collaborating with our innovative and forward-thinking partner in China to develop practical solutions to treat cancer patients worldwide. This new collaboration highlights the versatility of our Silica Matrix platform which is suitable for therapeutic applications in oncology. We estimate that in the future, many treatment modalities for cancer diseases will be centered on long-acting controlled release products. Recently, we presented data on how widely used anticancer peptides goserelin and triptorelin can be formulated into Silica Matrix to produce injectable long-acting products.”
For further information, please contact:
At the company
+44 (0) 7968 726585
About Anticancer Bioscience
Anticancer Bioscience (ACB) is an international private company, commercializing discoveries emerging from China’s world-leading cancer research at the J. Michael Bishop Institute of Cancer Research. With pioneers in synthetic lethal approaches to precision oncology and experts in MYC biology and cell division, ACB was founded in 2016 in Chengdu, China. ACB is based on over 20 years of collaborative research between the founder Dr. Dun Yang and his Nobel laureate mentor Dr. J. Michael Bishop. It has raised CNY131M (around USD21M) and has around 50 employees in Chengdu, China, Hyderabad, India, Sydney, Australia, St Andrews, UK, and San Francisco, USA.